RxDoctor Payments Data

Troy Martin, MD

Family Medicine · Lafayette, LANPI 1710907761

Payments from drug & device makers

$4,313in general payments, 2019–2025

Across 218 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Pfizer$477
  • Axsome Therapeutics, Inc.$223
  • Abbott$133
  • Idorsia Pharmaceuticals US Inc$95
  • plus $249 from 9 others

What the payments were for

  • Food & beverage$4,28599%
  • Education$140%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,313 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$266,625
Medicare patients
557
Services billed
6,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide207$268,769
RybelsusSemaglutide16$32,371
MounjaroTirzepatide23$32,069
FarxigaDapagliflozin Propanediol21$18,943
JardianceEmpagliflozin11$18,481
Tresiba Flextouch U-100Insulin Degludec26$16,194
EliquisApixaban21$16,171
XareltoRivaroxaban20$15,468
Repatha SureclickEvolocumab13$15,458
ElmironPentosan Polysulfate Sodium12$13,830
Rosuvastatin Calcium618$8,685
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$8,536
TrintellixVortioxetine Hydrobromide11$6,344
Pantoprazole Sodium208$4,301
Gabapentin163$3,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,040$301,140223 claims
Lilly USA, LLCMounjaro$76$32,06923 claims
AstraZenecaFarxiga$29$18,94321 claims
PfizerEliquis$477$16,17121 claims
Johnson & JohnsonXarelto$20$15,46820 claims
AbbVieSynthroid$1,095$2,93941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →